DALLAS, Sept. 2, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Chinese vaccine maker Sinovac Biotech Ltd. (AMEX:SVA). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Sinovac Biotech Ltd. (AMEX:SVA) should be of particular interest to other biotechnology companies: Amgen Inc. (Nasdaq:AMGN), Biogen Idec Inc. (Nasdaq:BIIB), Genzyme Corp. (Nasdaq:GENZ) and Gilead Sciences Inc. (Nasdaq:GILD).
It is available at: http://www.stockpreacher.com/n/SVA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Sinovac Biotech Ltd. (SVA) is an emerging China-based biotechnology company focused on the development, manufacturing and commercialization of human vaccines against infectious diseases. The Company's portfolio of products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. Its Panflu(tm) vaccine, which protects against the H5N1 influenza virus, has already been approved for government stockpiling.
In the report, the analyst notes:
"On August 31, SVA announced its H1N1 vaccine has passed experts evaluation organized by SFDA, China's competent authority of drug regulation, pushing the Company's shares to hit a record high. According to the Company's press release, the H1N1 vaccine's results demonstrated to have a good safety profile and immunogenicity factors that reach the EU criterion after a single shot, with experts unanimously agreeing that the Company's H1N1 vaccine is applicable to all people from three to 60 years of age; and the vaccination schedule is single shot. The Company looks forward to obtaining the production license within one week.
"SVA shares were boosted last week, also helping the Swine and Bird Flu Stocks Index increase by 4.5% on news that the Company was chosen as one of the four manufacturers to supply Beijing with seasonal flu vaccine for 2009. According to the report, the Company will provide the city with its split viron vaccine, Anflu(r), which is also hoped to provide H1N1 swine flu protection."
To read the entire report visit: http://www.stockpreacher.com/n/SVA
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.